feeds

2018

In this update from the EU Early Warning System, the EMCDDA aims to provide insights into what is happening with new psychoactive substances in Europe, based on data from the agency’s early warning and risk-assessment activities. This report covers the period from January 2016 until December 2017.

2018

The Trends and Developments report presents a top-level overview of the drug phenomenon in Europe, covering drug supply, use and public health problems as well as drug policy and responses. Together with the online Statistical Bulletin and 30 Country Drug Reports, it makes up the 2018 European Drug Report package.

2018
Supervised drug consumption facilities, where illicit drugs can be used under the supervision of trained staff, have been operating in Europe for the last three decades. These facilities primarily aim to reduce the acute risks of disease transmission through unhygienic injecting, prevent drug-related overdose deaths and connect high-risk drug users with addiction treatment and other health and social services.
07.06.2018
2018

In a new update from the EU Early Warning System (EWS) on new psychoactive substances (NPS) (1), the EMCDDA releases today its latest insights in this area entitled Fentanils and synthetic cannabinoids: driving greater complexity into the drug situation.

07.06.2018
2018

Evidence of increased cocaine availability is highlighted by the EMCDDA today in its European Drug Report 2018: Trends and Developments released in Brussels. The development occurs in the context of a dynamic drug market which is able to adapt rapidly in response to drug control measures.

2018

This report presents the top-level overview of the drug phenomenon in Norway, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise 

2018

This report presents the top-level overview of the drug phenomenon in Hungary, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2018

This report presents the top-level overview of the drug phenomenon in Denmark, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise.

2018

This report presents the top-level overview of the drug phenomenon in Belgium, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise.

2018

This brochure provides an overview of the 2018 European Drug Report package and includes a brief summary of the main headlines. 

2018

This report presents the top-level overview of the drug phenomenon in the Netherlands, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2015 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2018

This report presents the top-level overview of the drug phenomenon in Turkey, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2018

This report presents the top-level overview of the drug phenomenon in Germany, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2018

This report presents the overview of the drug phenomenon in France, covering drug supply, use and public health problems, as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2018

This report looks at the use of new psychoactive substances (NPS) in prison settings. This is a rapidly developing phenomenon, but empirical data are currently scarce and patchy. There is growing evidence that NPS are responsible for a large share of drug-related problems in some European prisons and appropriate responses are mostly lacking. This preliminary analysis is the outcome of a targeted rapid information assessment or ‘trendspotter’ study carried out by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) between August and December 2017.

2018

Benzodiazepines are a widely prescribed group of medicines with a range of clinical uses, including the treatment of anxiety and insomnia and the management of alcohol withdrawal. For a number of reasons this group of medicines are often misused by high-risk opioid users and are associated with morbidity and mortality among this group. This analysis considers the significance of this problem and its impact for the health and drug treatment of opioid users.

01.06.2018
2018

This week, EMCDDA Director Alexis Goosdeel and members of his staff have been visiting IN-Mouraria, a low-threshold harm-reduction centre based in Lisbon. In 2019, the centre will become a managing partner of one of the new drug consumption rooms (DCRs) to be implemented in the capital by the Lisbon Town Hall.

2018

Homicide is a violent act that generates high social costs. In particular, drug-related homicide (DRH) has the potential to act as an indicator of wider drug-related crime. Comparing DRH levels between countries with data on this topic can be a valuable tool for identifying trends and new threats. As part of its programme for developing and improving drug supply indicators, the EMCDDA has been expanding its monitoring to include measures of wider drug-related crime, including DRH. However, there appears to be a significant gap in the available European data on this topic.

25.05.2018
2018

An EMCDDA Paper released today provides an overview of the information available on drug-related homicide (DRH) in Europe. This first snapshot provides practitioners and policymakers with the current state of the art on this topic.

24.05.2018
2018

EMCDDA Director Alexis Goosdeel will today address the 38th Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) taking place on 23 and 24 May in Bucharest. A key theme on the congress programme is the emergence of new psychoactive substances (NPS).

2018

What are the most (cost-) effective ways to prevent and control communicable diseases in prison settings? In their joint public health Guidance, ECDC and the EMCDDA, present the evidence on active case finding as a key measure to diagnose communicable diseases early. The two agencies advise to actively offer testing for hepatitis B, hepatitis C and HIV to all people in prison and to conduct universal testing for tuberculosis at prison entry.

23.05.2018
2018

What are the most (cost-) effective ways to prevent and control communicable diseases in prison settings? In their joint public health Guidance, ECDC and the EMCDDA present evidence on active case finding as a key measure to diagnose communicable diseases early. The publication is launched in the first Spring European Hepatitis-HIV Testing Week (18–25 May 2018).

23.05.2018
2018

What is the impact of cannabis use on driving? Do edible and smoked cannabis products affect drivers in the same way? These are among the questions addressed in a new policy briefing on cannabis and driving, published today.

2018

With cannabis use and policy evolving internationally, drug-impaired driving has become an increasingly relevant policy issue. This briefing aims to provide those concerned with policy developments in the field of cannabis with a brief overview of current knowledge and the latest developments in the area of driving.

15.05.2018
2018

EMCDDA Director Alexis Goosdeel will address a conference hosted by the Lithuanian Drug, Tobacco and Alcohol Control Department (NTAKD) in Vilnius today, as the organisation prepares to present a new strategy (2018–2028) to the Lithuanian parliament and government.

Dedicated to Lithuania’s drug policy review, with its human rights and health approach, the conference will underline the importance of a balanced and long-term drug policy, geared towards the creation of a healthy and safe society.

2018

This publication presents the data and findings of the risk assessment on 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 14 May 2018, the Council decided that CUMYL-4CN-BINACA should be subject to control measures across the Member States.

2018

This publication presents the data and findings of the risk assessment on N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 14 May 2018, the Council decided that ADB-CHMINACA should be subject to control measures across the Member States.

14.05.2018
2018

Today the European Union has decided to subject two new synthetic cannabinoids to control measures across the 28 Member States. The substances in question are ADB-CHMINACA and CUMYL-4CN-BINACA, which have been raising health concerns in Europe.

27.04.2018
2018

The European Drug Report 2018: Trends and Developments will be launched on 7 June in Brussels. Accompanying the report will be the 2018 Statistical Bulletin, and 30 Country Drug Reports, presenting summaries of national drug phenomena in the EU-28, Turkey and Norway.

2018

Darknet markets — also known as cryptomarkets — provide a largely anonymous platform for trading in a range of illicit goods and services. It is estimated that around two thirds of the offers on darknet markets are drug-related. Drug sales on these markets, although modest when compared to the overall retail drug market, are significant and appear to be expanding.  EU-based suppliers are important players in the darknet ecosystem, the evolution of which is shown in this timeline.

Loading